Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Dec. 12, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0332255/Brain-Hemorrhage-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global brain hemorrhage therapeutics market. The report identifies the key trends shaping and driving the global brain hemorrhage therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global brain hemorrhage sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global brain hemorrhage therapeutics market was worth $358m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 3% to $452m by 2018. The slow growth in the brain hemorrhage therapeutics market is largely due to its stable prevalence, a high mortality rate and a weak pipeline of only two company sponsored drugs. The main risk factors associated with brain hemorrhage are lifestyle factors such as smoking, obesity and alcohol consumption. The most common therapies are prescribed off-label, such as anti-hypertensive agents (labetalol and nicardipine), hemostatic agents (vitamin K and rfVIIa), antiepileptic drugs (phenytoin and lorazepam) and osmotherapy (mannitol 20%) which provide symptomatic treatment but lack superior safety and efficacy. The market does not have any approved therapies. These factors will result in the slow growth of the global brain hemorrhage therapeutics market to 2018.
GlobalData has found that the brain hemorrhage therapeutics market has high unmet needs, suggesting that the current market is not well served by the current treatment options. Moreover, these treatment options are not approved and are used as off-label. The market is dominated by off-label and generic medications which include antihypertensive agents, hemostatic agents, antiepileptic agents, and osmotherapy. Absence of approved therapies for brain hemorrhage clearly establishes that the current brain hemorrhage therapeutics market has high unmet need and there is scope for new entrants exhibiting superior safety and efficacy.
Scope
The report provides information on the key drivers and challenges of the brain hemorrhage therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) brain hemorrhage market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Most of the clinical trials are conducted by academic institutions, currently only GLP-1 CellBeads and PG2 are the drugs sponsored by CellMed/BTG and PhytoHealth Corporation respectively. Of the total number drugs in the pipeline, four drugs are first-in-class and the remaining 12 drugs are generics. The mechanism of action of one drug in phase 0 is unknown. The first-in-class molecules have a distinct advantage over the currently marketed products with regards to better symptomatic management.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the brain hemorrhage therapeutics market.
- Analysis of key recent licensing and partnership agreements in brain hemorrhage therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global brain hemorrhage therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global brain hemorrhage therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global brain hemorrhage therapeutics market landscape? – Identify, understand and capitalize
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Brain Hemorrhage Therapeutics - Introduction 6
2.1 Overview 6
2.1.1 Diagnostic and Statistical Manual of Cerebrovascular Diseases - Stroke Classification 7
2.1.2 WHO Stroke Definition 8
2.1.3 Quality of Life 9
2.2 Epidemiology 9
2.2.1 Worldwide Prevalence 9
2.2.2 Incidence of Cerebral Hemorrhage 10
2.2.3 Epidemiology Trends 10
2.2.4 Age, Gender and Ethnicity 11
2.2.5 Economic Burden 11
2.3 Etiology and Pathophysiology 13
2.3.1 ICH 13
2.3.2 SAH 14
2.3.3 Risk Factors 14
2.4 Signs and Symptoms 16
2.4.1 The Face Arm Speech Test 17
2.5 Diagnosis 17
2.5.1 Other Tests 18
2.5.2 The Glasgow Coma Scale 18
2.5.3 Referral Pathway 20
2.6 Treatment and Management 21
2.6.1 Emergency Management 23
2.6.2 Prevention 25
2.6.3 Rehabilitation 26
2.7 GlobalData Pipeline Report Guidance 27
3 Brain HemorrhageTherapeutics - Market Characterization 28
3.1 Overview 28
3.2 Brain Hemorrhage Therapeutics Market Size (2005 - 2010) - Global 28
3.3 Brain HemorrhageTherapeutics Market Forecast (2010-2018) - Global 29
3.4 Brain Hemorrhage Therapeutics Market Size (2005-2010) - The US 30
3.5 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - The US 31
3.6 Brain Hemorrhage Therapeutics Market Size (2005-2010) - France 32
3.7 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - France 33
3.8 Brain Hemorrhage Therapeutics Market Size (2005-2010) - Germany 34
3.9 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - Germany 35
3.10 Brain Hemorrhage Therapeutics Market Size (2005-2010) - Italy 36
3.11 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - Italy 37
3.12 Brain Hemorrhage Therapeutics Market Size (2005-2010) - Spain 38
3.13 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - Spain 39
3.14 Brain Hemorrhage Therapeutics Market Size (2005-2010) - The UK 40
3.15 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - The UK 41
3.16 Brain Hemorrhage Therapeutics Market Size (2005-2010) - Japan 42
3.17 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) - Japan 43
3.18 Drivers and Barriers for the Brain Hemorrhage Therapeutics Market 44
3.18.1 Drivers for the Brain Hemorrhage Therapeutics Market 44
3.18.2 Barriers for the Brain Hemorrhage Therapeutics Market 44
3.19 Opportunity and Unmet Need 45
3.20 Key Takeaway 45
4 Brain HemorrhageTherapeutics - Competitive Assessment 46
4.1 Overview 46
4.2 Strategic Competitor Assessment 46
4.3 Product Profiles for the Major Off-Label Marketed Products in the Brain Hemorrhage Market 47
4.3.1 Antihypertensive 47
4.3.2 Hemostatic Therapy 47
4.3.3 Antiepileptic Drugs 48
4.3.4 Osmotherapy 49
4.4 Key Takeaway 49
5 Brain Hemorrhage Therapeutics - Pipeline Assessment 50
5.1 Overview 50
5.2 Strategic Pipeline Assessment 50
5.3 Brain Hemorrhage Therapeutics Pipeline - Pipeline by Phases of Development 50
5.3.1 Brain Hemorrhage Therapeutics - Phase III Pipeline 50
5.3.2 Brain Hemorrhage Therapeutics - Phase II Pipeline 51
5.3.3 Brain Hemorrhage Therapeutics - Phase I/II Pipeline 51
5.3.4 Brain Hemorrhage Therapeutics - Phase I Pipeline 51
5.3.5 Brain Hemorrhage Therapeutics - Phase 0 Pipeline 51
5.4 Brain Hemorrhage Therapeutics Market - Pipeline by Mechanism of Action 52
5.5 Technology Trends Analytical Framework 53
5.6 Brain Hemorrhage Therapeutics - Promising Drugs Under Development 54
5.7 Molecule Profile for Promising Drugs Under Development 54
5.7.1 GLP-1 CellBeads 54
5.8 Key Takeaway 55
6 Brain Hemorrhage Therapeutics - Clinical Trials Mapping 56
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 56
6.2 Clinical Trials by Phase 57
6.3 Clinical Trials by Trial Status 58
6.4 Prominent Sponsors 59
6.5 Top Companies Participating in Brain Hemorrhage Therapeutics Clinical Trials 61
7 Brain HemorrhageTherapeutics - Strategic Assessment 62
7.1 Key Events Impacting the Future Market 62
7.2 Future Market Competition Scenario 63
8 Brain HemorrhageTherapeutics - Future Players 64
8.1 Introduction 64
8.2 BTG 64
8.2.1 Company Overview 64
8.2.2 Financial Overview 65
8.2.3 Business Description 65
8.2.4 Brain Hemorrhage Therapeutics Pipeline 65
9 Brain Hemorrhage Therapeutics Market - Appendix 66
9.1 Market Definitions 66
9.2 Abbreviations 66
9.3 Research Methodology 67
9.3.1 Coverage 67
9.3.2 Secondary Research 68
9.3.3 Forecasting 68
9.3.4 Primary Research 70
9.3.5 Expert Panels 70
9.4 Contact Us 70
9.5 Disclaimer 70
9.6 Bibliography 71
List of Tables
Table 1: Stroke and Stroke Risk Factors using International Classification of Diseases, Revisions 9 and 10 7
Table 2: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases, The US, 2010 12
Table 3: Economic Burden of Stroke 13
Table 4: Intravenous Antihypertensive Agents for Acute Intracerebral Hemorrhage 24
Table 5: Brain Hemorrhage Therapeutics, Global, Market Revenue ($m), 2005-2010 28
Table 6: Brain Hemorrhage Therapeutics, Global, Revenue Forecasts ($m), 2010-2018 29
Table 7: Brain HemorrhageTherapeutics Market, The US, Revenue ($m), 2005 - 2010 30
Table 8: Brain Hemorrhage Therapeutics Market, The US, Revenue ($m),2010-2018 31
Table 9: Brain Hemorrhage Therapeutics, France, Market Revenue ($m), 2005-2010 32
Table 10: Brain Hemorrhage Therapeutics, France, Revenue Forecasts ($m), 2010-2018 33
Table 11: Brain Hemorrhage Therapeutics, Germany, Market Revenue ($m), 2005-2010 34
Table 12: Brain Hemorrhage Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018 35
Table 13: Brain Hemorrhage Therapeutics, Italy, Market Revenue ($m), 2005-2010 36
Table 14: Brain Hemorrhage Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018 37
Table 15: Brain Hemorrhage Therapeutics, Spain, Market Revenue ($m), 2005-2010 38
Table 16: Brain Hemorrhage Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018 39
Table 17: Brain Hemorrhage Therapeutics, The UK, Market Revenue ($m), 2005-2010 40
Table 18: Brain Hemorrhage Therapeutics, the UK, Revenue Forecasts ($m), 2010-2018 41
Table 19: Brain Hemorrhage Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 42
Table 20: Brain Hemorrhage Therapeutics Market, Japan, Forecast ($m), 2010 - 2018 43
Table 21: Brain Hemorrhage Therapeutics - Phase III Pipeline, 2011 50
Table 22: Brain Hemorrhage Therapeutics - Phase II Pipeline, 2011 51
Table 23: Brain HemorrhageTherapeutics - Phase I Pipeline, 2011 51
Table 24: Brain HemorrhageTherapeutics- Preclinical Pipeline, 2011 51
Table 25: Brain HemorrhageTherapeutics- Phase 0 Pipeline, 2011 51
Table 26: Brain Hemorrhage Therapeutics - Most Promising Drugs Under Development, 2011 54
Table 27: Brain Hemorrhage Therapeutics - Clinical Trials by Country, 2011 56
Table 28: Brain Hemorrhage Therapeutics - Clinical Trials by Phase, 2011 57
Table 29: Brain Hemorrhage Therapeutics - Clinical Trials by Status, 2011 58
Table 30: Brain Hemorrhage Therapeutics - Prominent Sponsors, 2011 60
Table 31: Brain Hemorrhage Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 61
Table 32: BTG - Brain Hemorrhage Therapeutics Pipeline Products, 2011 65
1.2 List of Figures
Figure 1: Physiological Difference between Acute Ischemic Stroke and Hemorrhagic Stroke 6
Figure 2: Stroke Compared with Other Causes of Death 7
Figure 3: Burst and Breaks: Causes of Hemorrhagic Stroke 8
Figure 4: Worldwide Prevalence of Stroke 9
Figure 5: Percentage Breakdown of Direct Costs after Stroke 11
Figure 6: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases, The US, 2010 12
Figure 7: Computerized Tomography (CT) Images of the Common Sites of Intracerebral Hemorrhage Attributed to Hypertension 13
Figure 8: Subarachnoid Hemorrhage Caused by Ruptured Aneurysm 14
Figure 9: Stroke Risk Scorecard 16
Figure 10: The Face Arm Speech Test 17
Figure 11: The Glasgow Coma Scale 19
Figure 12: Referral Pathway for Brain Hemorrhage 20
Figure 13: Treatment Algorithm for Cerebral Hemorrhage 21
Figure 14: Treatment Stages for Brain Hemorrhage 22
Figure 15: Emergency Management Algorithm for Patients with Intracerebral Hemorrhage 23
Figure 16: Brain Hemorrhage Therapeutics, Global, Market Revenue ($m), 2005-2010 28
Figure 17: Brain Hemorrhage Therapeutics, Global, Market Revenue ($m), 2010-2018 29
Figure 18: Brain HemorrhageTherapeutics Market, The US, Revenue ($m), 2005-2010 30
Figure 19: Brain Hemorrhage Therapeutics Market, The US, Forecast ($m), 2010 - 2018 31
Figure 20: Brain Hemorrhage Therapeutics Market, France, Revenue ($m), 2005 - 2010 32
Figure 21: Brain Hemorrhage Therapeutics, France, Revenue Forecasts ($m), 2010-2018 33
Figure 22: Brain Hemorrhage Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 34
Figure 23: Brain Hemorrhage Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018 35
Figure 24: Brain Hemorrhage Therapeutics, Italy, Market Revenue ($m), 2005-2010 36
Figure 25: Brain Hemorrhage Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018 37
Figure 26: Brain Hemorrhage Therapeutics, Spain, Market Revenue ($m), 2005-2010 38
Figure 27: Brain Hemorrhage Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018 39
Figure 28: Brain Hemorrhage Therapeutics, The UK, Market Revenue ($m), 2005-2010 40
Figure 29: Brain Hemorrhage Therapeutics, The UK, Revenue Forecasts ($m), 2010-2018 41
Figure 30: Brain Hemorrhage Therapeutics, Japan, Market Revenue ($m), 2005-2010 42
Figure 31: Brain Hemorrhage Therapeutics Market, Japan, Forecast ($m), 2010 - 2018 43
Figure 32: Opportunity and Unmet Need in the Brain Hemorrhage Therapeutics Market, 2010 45
Figure 33: Brain Hemorrhage Therapeutics, Strategic Competitor Assessment, 2010 46
Figure 34: Brain Hemorrhage Therapeutics - Pipeline by Phase of Development, 2011 50
Figure 35: Brain Hemorrhage Market - Clinical Pipeline by Mechanism of Action, 2011 52
Figure 36: Brain Hemorrhage Therapeutics - Technology Trends Analytics Framework, 2011 53
Figure 37: Brain Hemorrhage Therapeutics - Technology Trends Analytics Framework - Description, 2011 54
Figure 38: Brain Hemorrhage Therapeutics - Clinical Trials by Region, 2011 56
Figure 39: Brain Hemorrhage Therapeutics - Clinical Trials by Phase, 2011 57
Figure 40: Brain Hemorrhage Therapeutics - Clinical Trials by Status, 2011 58
Figure 41: Brain Hemorrhage Therapeutics - Overall Sponsors, 2011 59
Figure 42: Brain Hemorrhage Therapeutics - Prominent Sponsors, 2011 59
Figure 43: Brain Hemorrhage Therapeutic - Top Companies Participating in Therapeutics Clinical Trials, 2011 61
Figure 44: Brain Hemorrhage Therapeutics, Key Events Impacting Future Market 62
Figure 45: Brain Hemorrhage Therapeutics, Strategic Assessment, 2011 63
Figure 46: Brain Hemorrhage Therapeutics, Clinical Pipeline by Company, 2011 64
Figure 47: GlobalData Market Forecasting Model 69
Companies mentioned
BTG
To order this report:
Pathology Industry: Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article